News
-
-
COMMUNIQUÉ DE PRESSE
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
Cyprumed and MSD sign a Non-Exclusive License and Option Agreement for the Development of Oral Peptide Therapeutics, potentially unlocking new opportunities in peptide therapeutics -
COMMUNIQUÉ DE PRESSE
EMERAM achieves success in challenging market environment: four investments and one exit in 2024, double-digit growth expected in 2025
EMERAM Capital Partners achieves success with four investments and one exit in 2024, predicts double-digit growth for 2025 amidst challenging market conditions -
-
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Cie du Bois Sauvage : Rachat d’actions propres – semaine du 07/04/2025 au 11/04/2025
La Compagnie du Bois Sauvage annonce le rachat d'actions propres sur le marché réglementé NYSE Euronext Bruxelles du 07/04/2025 au 11/04/2025, conformément à l'autorisation de l'assemblée générale extraordinaire d'avril 2021 -
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Holding AG Releases Financial Results for 2024 and Announces Guidance for the 2025 Financial Year
Pentixapharm Holding AG releases 2024 financial results with EUR 12.8 million net loss and guides for EUR 23.5 million loss in 2025, focusing on R&D and operating expenses
